ENDRA Life Sciences (NASDAQ:NDRA) Stock Price Up 1.9% – Should You Buy?

ENDRA Life Sciences Inc. (NASDAQ:NDRA)’s stock price shot up 1.9% during mid-day trading on Friday. The company traded as high as $6.32 and last traded at $6.04. 37,386 shares were traded during trading, a decline of 40% from the average daily volume of 62,664 shares. The stock had previously closed at $5.93.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on NDRA shares. Weiss Ratings upgraded ENDRA Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 10th. Ascendiant Capital Markets dropped their price objective on ENDRA Life Sciences from $27.00 to $25.00 and set a “buy” rating for the company in a research note on Monday, June 1st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, ENDRA Life Sciences presently has an average rating of “Hold” and an average price target of $25.00.

ENDRA Life Sciences Stock Up 1.9%

The company has a market capitalization of $9.06 million, a PE ratio of -0.95 and a beta of -0.05. The stock’s fifty day moving average price is $5.14 and its two-hundred day moving average price is $4.95.

ENDRA Life Sciences (NASDAQ:NDRA) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.21. On average, equities research analysts forecast that ENDRA Life Sciences Inc. will post -4.11 EPS for the current year.

Institutional Trading of ENDRA Life Sciences

An institutional investor recently bought a new stake in ENDRA Life Sciences stock. Citizens Financial Group Inc. RI acquired a new position in ENDRA Life Sciences Inc. (NASDAQ:NDRA) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 28,400 shares of the company’s stock, valued at approximately $151,000. Citizens Financial Group Inc. RI owned approximately 2.24% of ENDRA Life Sciences at the end of the most recent quarter. Institutional investors and hedge funds own 1.19% of the company’s stock.

ENDRA Life Sciences Company Profile

ENDRA Life Sciences Inc is a medical technology company developing noninvasive imaging solutions for the assessment of tissue properties. Its technology is designed to expand the capabilities of conventional ultrasound systems by providing quantitative information that may support the detection and monitoring of disease.

The company’s lead platform, TAEUS (Thermo-Acoustic Enhanced UltraSound), is being developed initially for the evaluation of liver fat associated with metabolic dysfunction-associated steatotic liver disease and related conditions.